Ennature Bio Pharma Board Meeting on Nov 12 to Approve Q2 Results

Ennature Bio Pharma Ltd has announced that its Board of Directors will convene on November 12, 2026. The primary agenda item for this meeting is to consider and approve the unaudited financial results for the second quarter ended September 30, 2026. In line with SEBI regulations, the company has also informed that the trading window for its securities, which was closed from November 4, 2026, will remain shut until November 14, 2026. The financial results will be published on the company's website.